

IRISH MEDICINES BOARD ACT 1995, as amended

Medicinal Products (Control of Placing on the Market) Regulations, 2007, as amended

PA0970/032/002

Case No: 2065373

The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to

AstraZeneca UK Limited

600 Capability Green, Luton, LU1 3LU, United Kingdom

an authorisation, subject to the provisions of the said Regulations, in respect of the product

Betaloc 50mg Tablets

the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document.

This authorisation, unless previously revoked, shall continue in force from **26/05/2010**.

Signed on behalf of the Irish Medicines Board this

A person authorised in that behalf by the said Board.

Part II

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Betaloc 50mg Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains Metoprolol tartrate 50mg.

Excipients: Each tablet contains 17.5mg lactose monohydrate

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Tablet.

White to off-white, circular, biconvex tablet, scored and engraved 'A/BB' on one side.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

In the management of hypertension and angina pectoris.

Cardiac arrhythmias, especially supraventricular tachyarrhythmias.

Adjunct to the treatment of hyperthyroidism.

Early intervention with Betaloc in acute myocardial infarction reduces infarct size and the incidence of ventricular fibrillation. Pain relief may also decrease the need for opiate analgesics.

Betaloc has been shown to reduce mortality when administered to patients with acute myocardial infarction.

Prophylaxis of migraine.

4.2 Posology and method of administration

The tablets should be taken on an empty stomach.

The dose must always be adjusted to the individual requirements of the patient. The following are guidelines:

Hypertension

The recommended maintenance dosage in patients with hypertension is 100mg-200mg daily, given as a single dose in the morning or in divided doses (morning and evening). Begin with 50mg twice daily or 100mg once daily. Dose increments should be at intervals thereafter according to individual patient responses. Maximum dose, usually 200mg daily. Doses up to 400mg daily have been used. If needed, other antihypertensive agents may be added.

Long-term antihypertensive treatment with metoprolol in daily doses of 100-200mg has been shown to reduce total mortality, including sudden cardiovascular death, stroke, and coronary events in hypertensive patients.

Angina Pectoris

The recommended dosage is 100-200mg daily, given in divided doses (morning and evening). Begin with 50mg twice daily. Dose increments should be at intervals thereafter according to individual patient responses. Maximum dose, usually 200mg daily (in divided doses). Doses up to 300mg daily (in divided doses) have been used. If needed, other antianginal agents may be added.

Cardiac Arrhythmias

The recommended dosage is 100-200mg daily given in divided doses (morning and evening). If needed, other antiarrhythmic agents may be added.

Hyperthyroidism

The recommended dosage is 50mg four times a day.

Myocardial Infarction*Early intervention*

To achieve optimal benefits from intravenous Betaloc suitable patients should present within 12 hours of the onset of chest pain. Therapy should commence with 5mg i.v. every 2 minutes to a maximum of 15mg total as determined by blood pressure and heart rate. The second or third dose should not be given if the systolic blood pressure is <90mmHg, the heart rate is <40 beats/min and the P-Q time is >0.26 seconds, or if there is any aggravation of dyspnoea or cold sweating. Oral therapy should commence 15 minutes after the last injection with 50mg every 6 hours for 48 hours. Patients who fail to tolerate the full intravenous dose should be given half the suggested oral dose.

Maintenance

The usual maintenance dose is 200mg daily, given in divided doses.

Migraine Prophylaxis

The recommended dosage is 100-200mg daily, given in divided doses (morning and evening).

Impaired Renal Function

Dose adjustment is generally not needed in patients with impaired renal function.

Impaired Hepatic Function

Dose adjustment is normally not needed in patients suffering from liver cirrhosis because metoprolol has a low protein binding (5-10%). However, a reduction in dosage may be necessary, according to the severity of hepatic impairment.

Elderly

Several studies indicate that age-related physiological changes have negligible effects on the pharmacokinetics of metoprolol.

Children

There is limited experience with metoprolol treatment in children.

4.3 Contraindications

Betaloc, as with other beta-blockers, should not be used in patients with any of the following:

- AV block of second- or third-degree,
- Unstable decompensated cardiac failure (pulmonary oedema, hypoperfusion or hypotension),
- Continuous or intermittent inotropic therapy acting through beta-receptor agonism,
- Bradycardia, (<45bpm),
- Sick sinus syndrome,
- Cardiogenic shock,
- Severe peripheral arterial circulatory disorder,
- Untreated phaeochromocytoma,
- Metabolic acidosis.

Known hypersensitivity to any component of Betaloc or other beta-blockers.

Betaloc is also contra-indicated when suspected acute myocardial infarction is complicated by bradycardia (<45bpm), first degree heart block (the P-Q interval is >0.24 sec) or systolic blood pressure <100mmHg.

4.4 Special warnings and precautions for use

Betaloc as with other beta-blockers:

- Should not be withdrawn abruptly. When possible, Betaloc should be withdrawn gradually over a period of 10-14 days, in diminishing doses to 25mg daily for the last 6 days. During its withdrawal patients should be kept under close surveillance, especially those with known ischaemic heart disease. The risk for coronary events, including sudden death, may increase during the withdrawal of beta-blockade.
- Must be reported to the anaesthetist prior to general anaesthesia. It is not generally recommended to stop Betaloc treatment in patients undergoing surgery. Acute initiation of high-dose metoprolol to patients undergoing non-cardiac surgery should be avoided, since it has been associated with bradycardia, hypotension and stroke including fatal outcome in patients with cardiovascular risk factors.
- Although contra-indicated in severe peripheral arterial circulatory disturbances (see Section 4.3, Contraindications), may also aggravate less severe peripheral arterial circulatory disorders.
- May be administered when heart failure has been controlled. Digitalisation and/or diuretic therapy should also be considered for patients with a history of heart failure, or patients known to have a poor cardiac reserve.
- May cause patients to develop increasing bradycardia, in such cases the Betaloc dosage should be reduced or gradually withdrawn.
- Due to the negative effect on conduction time, may aggravate pre-existing conduction time disorders of moderate degree, which may lead to AV block, and should only be given with caution to patients with first degree heart block.
- May increase the number and duration of angina attacks in patients with Prinzmetal's angina, due to unopposed alpha-receptor mediated coronary artery vasoconstriction. Betaloc is a beta₁-selective beta-blocker; consequently, its use may be considered although utmost caution must be exercised.
- May mask the early signs of acute hypoglycaemia, in particular tachycardia. During treatment with Betaloc, the risk of interfering with carbohydrate metabolism or masking hypoglycaemia is less than with non-selective beta-blockers.
- May mask the symptoms of thyrotoxicosis.
- May increase both the sensitivity towards allergens and the seriousness of anaphylactic reactions.

Although cardioselective beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers, these should be avoided in patients with reversible obstructive airways disease unless there are compelling clinical reasons for their use. When administration is necessary, these patients should be kept under close surveillance. The use of a beta₂-bronchodilator (e.g. terbutaline) may be advisable in some patients. The dosage of the beta₂-agonist may require an increase when treatment with Betaloc is commenced.

As with all beta-blockers, careful consideration should be given to patients with psoriasis before Betaloc is administered.

In the presence of liver cirrhosis the bioavailability of Betaloc may be increased.

In patients with a pheochromocytoma, an alpha-blocker should be given concomitantly.

In labile and insulin-dependent diabetes it may be necessary to adjust the hypoglycaemic therapy.

Intravenous administration of calcium antagonists of the verapamil-type should not be given to patients treated with beta-blockers.

The initial treatment of severe malignant hypertension should be so designed as to avoid sudden reduction in diastolic blood pressure with impairment of autoregulatory mechanisms.

This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Betaloc can reduce myocardial contractility and impair intracardiac conduction. Care should be exercised when drugs with similar activity, e.g. antiarrhythmic agents (of the quinidine type and amiodarone), or general anaesthetics, are given concurrently.

Increased negative inotropic and chronotropic effects may occur when Betaloc is given together with calcium antagonists of the verapamil and diltiazem type, causing bradycardia, hypotension and asystole. In patients treated with beta-blockers intravenous administration of calcium antagonists of the verapamil-type should not be given in combination.

Digitalis glycosides, in association with beta-blockers, may increase atrioventricular conduction time and may induce bradycardia.

Patients receiving concomitant treatment with sympathetic ganglion blocking agents, other beta-blockers (i.e. eye drops), or Mono Amine Oxidase (MAO) inhibitors should be kept under close surveillance.

If concomitant treatment with clonidine is to be discontinued, Betaloc should be withdrawn several days before clonidine.

Betaloc will antagonise the beta₁-effects of sympathomimetic agents but should have little influence on the bronchodilator effects of beta₂-agonists at normal therapeutic doses.

The administration of adrenaline (epinephrine) to patients undergoing beta-blockade can result in an increase in blood pressure and bradycardia although this is less likely to occur with beta₁-selective drugs.

Betaloc may impair the elimination of lidocaine.

Metoprolol is a metabolic substrate for the Cytochrome P450 isoenzyme CYP2D6. Drugs that act as enzyme-inducing and enzyme-inhibiting substances may exert an influence on the plasma level of metoprolol. Plasma levels of metoprolol may be raised by co-administration of compounds metabolised by CYP2D6, e.g. antiarrhythmics, antihistamines, histamine-2-receptor antagonists, antidepressants, antipsychotics, and COX-2-inhibitors. The plasma concentration of metoprolol is lowered by rifampicin and may be raised by alcohol and hydralazine.

As with other beta-blockers, concomitant therapy with dihydropyridines e.g. nifedipine, may increase the risk of hypotension, and cardiac failure may occur in patients with latent cardiac insufficiency.

Concomitant treatment with indometacin or other prostaglandin synthetase inhibiting drugs may decrease the antihypertensive effect of beta-blockers.

The beta-blocker may mask some of the symptoms of thyrotoxicosis and of hypoglycaemia by inhibition of sympathetic nerve functions. The effects of hypoglycaemic agents may be increased, particularly by the non-cardioselective beta-blockers. The dosages of oral antidiabetics and also of insulin may have to be readjusted in patients receiving beta-blockers. The tachycardia of hypoglycaemia may be modified.

As beta-blockers may affect the peripheral circulation, care should be exercised when drugs with similar activity e.g. ergotamine are given concurrently.

The effects of Betaloc and other antihypertensive drugs on blood pressure are usually additive. Care should be taken when combining with other antihypertensive drugs or drugs that might reduce blood pressure, such as tricyclic antidepressants, barbiturates and phenothiazines. However, combinations of antihypertensive drugs may often be used with benefits to improve control of hypertension.

4.6 Pregnancy and lactation

Pregnancy

Betaloc should not be used in pregnancy or nursing mothers unless the physician considers that the benefit outweighs the possible hazard to the foetus/infant. Beta-blockers reduce placental perfusion, which may result in intrauterine foetal death, immature and premature deliveries.

As with all beta-blockers, Betaloc may cause side-effects especially bradycardia and hypoglycaemia in the foetus, and in the newborn and breastfed infant. Betaloc has, however, been used in pregnancy associated hypertension under close supervision, after 20 weeks gestation. Although Betaloc crosses the placental barrier and is present in the cord blood, as yet no evidence of foetal abnormalities has been reported.

Lactation

The amount of metoprolol ingested via breast milk should not produce significant beta-blocking effects in the neonate if the mother is treated with the normal therapeutic doses.

4.7 Effects on ability to drive and use machines

Patients should know how they react to Betaloc before they drive or use machines because occasionally dizziness or fatigue may occur.

4.8 Undesirable effects

Betaloc is well tolerated and adverse reactions have generally been mild and reversible. The following events have been reported as adverse events in clinical trials or reported from routine use. A relationship to treatment with metoprolol has not always been established.

The following definitions of frequencies are used:

Very common ($\geq 10\%$), common (1-9.9%), uncommon (0.1-0.9%), rare (0.01-0.09%) and very rare ($< 0.01\%$).

Cardiovascular system

Common:	Bradycardia, postural disorders (very rarely with syncope), cold hands and feet, palpitations.
Uncommon:	Deterioration of heart failure symptoms, cardiogenic shock in patients with acute myocardial infarction*, first-degree heart block, oedema, precordial pain.
Rare:	Disturbances of cardiac conduction, cardiac arrhythmias.
Very rare:	Gangrene in patients with pre-existing severe peripheral circulatory disorders.

*Excess frequency of 0.4% compared with placebo in a study of 46,000 patients with acute myocardial infarction where the frequency of cardiogenic shock was 2.3% in the metoprolol group and 1.9% in the placebo group in the subset of patients with low shock risk index. The shock risk index was based on the absolute risk of shock in each individual patient derived from age, sex, time delay, Killip class, blood pressure, heart rate, ECG abnormality, and prior history of hypertension. The patient group with low shock risk index corresponds to the patients in which metoprolol is recommended for use in acute myocardial infarction.

Central nervous system

Very common:	Fatigue.
--------------	----------

Common: Dizziness, headache.
 Uncommon: Paraesthesiae, muscle cramps.

Gastrointestinal

Common: Nausea, abdominal pain, diarrhoea, constipation.
 Uncommon: Vomiting.
 Rare: Dry mouth.

Haematologic

Very rare: Thrombocytopenia.

Hepatic

Rare: Liver function test abnormalities.
 Very rare: Hepatitis.

Metabolism

Uncommon: Weight gain.

Musculoskeletal

Very rare: Arthralgia.

Psychiatric

Uncommon: Depression, concentration impairment, somnolence or insomnia, nightmares.
 Rare: Nervousness, anxiety, impotence/sexual dysfunction.
 Very rare: Amnesia/memory impairment, confusion, hallucinations.

Respiratory

Common: Dyspnoea on exertion.
 Uncommon: Bronchospasm.
 Rare: Rhinitis.

Sense organs

Rare: Disturbances of vision, dry and/or irritated eyes, conjunctivitis.
 Very rare: Tinnitus, taste disturbances.

Skin

Uncommon: Rash (in the form of urticaria psoriasiform and dystrophic skin lesions), increased sweating.
 Rare: Loss of hair.
 Very rare: Photosensitivity reactions, aggravated psoriasis.

4.9 Overdose

The symptoms of overdose may include bradycardia, hypotension, acute cardiac insufficiency and bronchospasm.

General treatment should include:

Close supervision, treatment in an intensive care ward, the use of gastric lavage, activated charcoal and a laxative to prevent absorption of any drug still present in the gastrointestinal tract, the use of plasma or plasma substitutes to treat hypotension and shock.

Excessive bradycardia can be countered with atropine 1-2 mg intravenously and/or a cardiac pacemaker. If necessary, this may be followed by a bolus dose of glucagon 10 mg intravenously. If required, this may be repeated or followed by an intravenous infusion of glucagon 1-10 mg/hour depending on response. If no response to glucagon occurs or if glucagon is unavailable, a beta adrenoceptor stimulant such as dobutamine 2.5 to 10 micrograms/kg/minute by intravenous infusion may be given.

Dobutamine, because of its positive inotropic effect could also be used to treat hypotension and acute cardiac insufficiency. It is likely that these doses would be inadequate to reverse the cardiac effects of beta blockade if a large overdose has been taken. The dose of dobutamine should therefore be increased if necessary to achieve the required response according to the clinical condition of the patient.

Administration of calcium ions may also be considered. Bronchospasm can usually be reversed by bronchodilators.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Metoprolol is a competitive β -adrenoceptor antagonist. It acts preferentially to inhibit β_1 -adrenoceptors (conferring some cardioselectivity), is devoid of intrinsic sympathomimetic activity (partial agonist activity) and possesses β -adrenoceptor blocking activity comparable in potency with propranolol.

A negative chronotropic effect on the heart is a consistent feature of metoprolol administration. Thus, cardiac output and systolic blood pressure rapidly decrease following acute administration.

5.2 Pharmacokinetic properties

Metoprolol tablets dissolve rapidly which results in a rapid and complete absorption with t_{\max} within 2 hours and consistent bioavailability data between different study populations.

Metoprolol undergoes oxidative metabolism in the liver primarily by the CYP2D6 isoenzyme.

Elimination is mainly via hepatic metabolism (>90%). Terminal half life is about 3-4 hours.

5.3 Preclinical safety data

The acute toxicity of metoprolol is low to moderate. Signs of toxicity are non-specific and do not indicate any target organ. Signs in rats and dogs indicate that metoprolol can exert a cardiopressive action at high plasma concentrations. Acute toxicity after oral administration is lower in rodents than in dogs.

There is no specific general toxicity after repeated administration to rats or dogs. Reproduction and mutagenicity studies have revealed no evidence of adverse effects.

Carcinogenicity studies in rats and mice have shown no increased incidence of neoplasms related to metoprolol.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Microcrystalline cellulose
Lactose monohydrate
Sodium starch glycollate
Colloidal anhydrous silica
Povidone
Magnesium stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf Life

5 years.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

Polypropylene securitainer with polyethylene cap - 56, 100 and 500 tablets

Thermoformed PVC/aluminium blister packs:

100 (10 x 10 blisters)

56 (4 x 14 blisters)

50 (5 x 10 blisters)

Not all pack sizes may be marketed.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

No special requirements.

7 MARKETING AUTHORISATION HOLDER

AstraZeneca UK Ltd.,
600 Capability Green,
Luton
LU1 3LU
United Kingdom

8 MARKETING AUTHORISATION NUMBER

PA 970/32/2

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 04 June 1975

Date of last renewal: 26 May 2010

10 DATE OF REVISION OF THE TEXT

May 2010